Astria Therapeutics (NASDAQ:ATXS) Stock Price Crosses Above 50 Day Moving Average of $3.31

Astria Therapeutics, Inc. (NASDAQ:ATXSGet Rating) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.31 and traded as high as $4.36. Astria Therapeutics shares last traded at $4.33, with a volume of 66,921 shares changing hands.

Astria Therapeutics Stock Performance

The firm’s fifty day simple moving average is $3.31 and its 200 day simple moving average is $4.96. The firm has a market cap of $56.36 million, a P/E ratio of -0.55 and a beta of 1.59.

Astria Therapeutics (NASDAQ:ATXSGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.45). On average, equities research analysts predict that Astria Therapeutics, Inc. will post -4.18 earnings per share for the current year.

Institutional Trading of Astria Therapeutics

A hedge fund recently raised its stake in Astria Therapeutics stock. Oppenheimer & Co. Inc. boosted its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXSGet Rating) by 78.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,816 shares of the biotechnology company’s stock after buying an additional 9,567 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.17% of Astria Therapeutics worth $118,000 as of its most recent SEC filing. Institutional investors own 51.79% of the company’s stock.

About Astria Therapeutics

(Get Rating)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.

Recommended Stories

Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with's FREE daily email newsletter.